Background While several studies have found fatigue to be the single most prevalent, severe, and disabling symptom in cancer patients – exceeding even pain – it remains both underrecognized and poorly treated by physicians (1). This Fast Fact reviews diagnostic and treatment approaches in the palliative care setting.

Characteristics of Cancer Related Fatigue (CRF) CRF is a persistent sense of tiredness/diminished energy related to cancer and/or its treatment, which is not relieved by rest, and which causes diminution in functional capacity and quality of life. Additional proposed ICD-10 features include: diminished concentration; diminished motivation; insomnia or hypersomnia; nonrestorative sleep; short-term memory deficits, and marked emotional reactivity to fatigue that are not primarily consequences of depression.

Causes CRF is often multifactorial, with biochemical, physiological, psychological, and behavioral dimensions that remain poorly defined. Assessment is aimed at identifying correctable causes and determining the impact of CRF on both patients and caregivers. Common causes of CRF include:

- Direct effect from cancer and/or treatments
- Sedating medications
- Deconditioning
- Psychiatric co-morbidities (e.g. depression, anxiety)
- Hypoxemia, or severe anemia (Hb ≤8 g/dL) and possibly moderate anemia (Hb ≤11g/dL)
- Systemic infection and/or significant organ dysfunction (e.g. heart, liver, kidney, lung)
- Electrolyte abnormalities (e.g. ↓Na⁺, ↓K⁺, ↓Mg²⁺, ↑Ca²⁺)
- Nutritional imbalance/impairment
- Sleep disturbance
- Uncontrolled pain

Specific Treatments should be directed toward correcting identifiable causes, e.g. elimination of sedating drugs, correction of anemia or electrolyte imbalance.

Non-Specific Treatments may help in reduce fatigue, optimize function, and promote adaptation.

- **Education**: Educate patient/family about CRF in order to normalize the symptom and promote adaptation/adjustment through setting realistic goals; modifying and prioritizing activities; and planning activities around diurnal variations in energy levels.
- **Exercise**: A meta-analysis suggested that aerobic exercise can improve cancer-related fatigue symptoms (3). Aerobic exercise (low to moderate intensity; progressive) is ideal, but benefits may also be realized with resistance training (4). A reasonable goal is 20-30 minutes of (cumulative) exercise per day, at least 3 days per week.
- **Drug Therapy**: There is little good data for non-specific drug therapy in CRF. The following drugs have been used with variable success:
  - **Psychostimulants**: While there is a growing literature on the use of psychostimulants for CRF, there is a lack of good controlled trials. **Methylphenidate**: a meta-analysis indicated superiority of methylphenidate over placebo for treatment of CRF (6). Start with 2.5-5 mg and titrate as necessary to 15-30 mg po at 08:00 and noon. **Modafanil**: pilot studies indicated efficacy in the treatment of fatigue associated with depression, multiple sclerosis, ALS, and HIV with potentially fewer side effects than other psychostimulants. However, a more recent meta-analysis showed no benefit over placebo (5). Suggested initial dosing is 50 mg po qam and titrate as necessary to 200-400 mg po qam. See Fast Facts #61 and 259.
  - **Corticosteroids**: These may provide a modest duration of benefit (2-4 weeks) offset by the potential for significant toxicity (6). Reported regimens have included prednisone 7.5-10 mg po qday; dexamethasone 1-4 mg po qday; methylprednisolone 32 mg po qday.
  - **Meggistrol acetate**: Two double-blind, crossover studies showed reduction in CRF with doses of 160 mg by mouth three times a day (7,8).
• **Dietary Supplements:** *Ginseng:* A randomized trial of 2000 mg of daily oral ginseng vs placebo showed significant improvement in cancer-related fatigue at 8 weeks with no adverse effects (9). *L-carnitine* has been investigated for CRF in a non-controlled fashion, but the quality of these studies have been suboptimal.

• **Complementary Therapies:** *Acupuncture:* a systemic review indicated potential benefit in CRF, but also cited a need for more rigorously designed trials before conclusions may be drawn (10).

**References**


**Version History:** This *Fast Fact* was originally edited by David E Weissman MD and published in January 2007. Copy-edited in April 2009. Re-copy edited in November 2015 by Mary G Rhodes, MD.

*Fast Facts and Concepts* are edited by Sean Marks MD (Medical College of Wisconsin) and associate editor Drew A Rosielle MD (University of Minnesota Medical School), with the generous support of a volunteer peer-review editorial board, and are made available online by the Palliative Care Network of Wisconsin (PCNOW); the authors of each individual *Fast Fact* are solely responsible for that *Fast Fact*’s content. The full set of *Fast Facts* are available at Palliative Care Network of Wisconsin with contact information, and how to reference *Fast Facts*.

**Copyright:** All *Fast Facts and Concepts* are published under a Creative Commons Attribution-NonCommercial 4.0 International Copyright ([http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)). *Fast Facts* can only be copied and distributed for non-commercial, educational purposes. If you adapt or distribute a *Fast Fact*, let us know!

**Disclaimer:** *Fast Facts and Concepts* provide educational information for health care professionals. This information is not medical advice. *Fast Facts* are not continually updated, and new safety information may emerge after a *Fast Fact* is published. Health care providers should always exercise their own independent clinical judgment and consult other relevant and up-to-date experts and resources. Some *Fast Facts* cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.